A new gene therapy called Zynteglo could eliminate iron-rich blood transfusions used to treat patients with beta thalassemia that causes severe anemia but it costs around $2.8 million. NBC News’ Anne ...
The development and approval of gene therapies has been a potential game changer for patients with beta-thalassaemia who have been dependent on regular red blood cell transfusions -- a substantial ...
Verve Therapeutics (VERV) is revolutionizing the approach to cardiovascular disease treatment through pioneering gene-editing therapies that provide lifelong cholesterol control after a single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results